GLP-1R Agonists Show Reproducible Evidence for Knee Osteoarthritis Symptom Relief, While Other Peptides Lack High-Quality Data
Background
Injectable peptides are increasingly promoted for musculoskeletal recovery, tissue repair, and performance enhancement in sports medicine. However, their rapid adoption has outpaced the availability of high-quality clinical evidence and regulatory consensus. Current standard-of-care often involves invasive procedures or symptomatic management, leaving a gap for non-surgical, regenerative solutions. This review aims to synthesize contemporary human and translational evidence for relevant peptides, addressing safety, quality, regulatory, and antidoping implications.
Study Design
Researchers conducted a structured narrative review, searching PubMed/MEDLINE, Embase, and Web of Science for studies published between January 1, 2020, and August 31, 2025. Eligible studies included randomized controlled trials, prospective human studies, and translational investigations directly applicable to musculoskeletal care. Non-injectable formulations and non-musculoskeletal indications were excluded. Results were synthesized qualitatively, and the risk of bias for human trials was appraised using standard tools to ensure a rigorous evaluation of the evidence.
Results
Five functional peptide classes relevant to sports medicine were identified. Among these, Glucagon-like peptide-1 receptor agonists (e.g., semaglutide) are the only class supported by reproducible randomized evidence for symptomatic improvement in knee osteoarthritis. These benefits are primarily mediated by clinically meaningful weight loss and putative anti-inflammatory effects, although structural cartilage modification remains unproven. Collagen-derived injectable preparations demonstrated preliminary postoperative symptom and early recovery benefits in small, single-center prospective human studies. Regenerative peptides (e.g., body protection compound-157 and thymosin derivatives) and growth hormone axis secretagogues (e.g., CJC-1295, ipamorelin, and tesamorelin) were identified as classes, but the provided abstract text does not detail specific findings or high-quality evidence for their efficacy in musculoskeletal applications. The overall landscape suggests a significant disparity in the quality and volume of evidence across different peptide classes. GLP-1R agonists (e.g., semaglutide) are the only injectable peptide class with reproducible randomized evidence for symptomatic improvement in knee osteoarthritis.
Key Findings
- Five functional injectable peptide classes relevant to sports medicine were identified.
- GLP-1R agonists (e.g., semaglutide) are the only class with reproducible randomized evidence for symptomatic improvement in knee osteoarthritis.
- Benefits of GLP-1R agonists are primarily mediated by weight loss and anti-inflammatory effects; structural cartilage modification is unproven.
- Collagen-derived injectable preparations show preliminary postoperative symptom/early recovery benefits in small, single-center human studies.
- Evidence for regenerative peptides (e.g., BPC-157, thymosin derivatives) and GH secretagogues (e.g., CJC-1295, ipamorelin, tesamorelin) remains limited or unproven in the provided abstract.
Why It Matters
This review highlights a critical distinction for peptide users and clinicians: only GLP-1R agonists currently possess reproducible, high-quality evidence for a specific musculoskeletal indication (knee osteoarthritis symptom relief). For other widely promoted peptides like BPC-157 or GH secretagogues, the evidence base remains largely preliminary or lacking in human trials. This means current protocols involving these other peptides for musculoskeletal repair or performance enhancement are largely speculative and not supported by robust clinical data. The clinical translation outlook for GLP-1R agonists in osteoarthritis is promising, potentially offering a non-surgical option, while other peptides require substantial further research to move beyond anecdotal use. Users should exercise caution and prioritize evidence-backed interventions.